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Abstract 
Optoacoustic tomography has been used for the detection of pancreatic ductal 
adenocarcinoma targeted by pH Low Insertion Peptide (pHLIP) conjugated to near infrared 
fluorescent dye. It was proved that tumor targeting is a pH-dependent. The approach could 
have major implication for detection and monitoring of pancreatic and other cancers.  
 
Commentary on Kimbrough et al. 
 
In this issue of Clinical Cancer Research, Kimbrough and colleagues (1) report that pH-sensitive 
pHLIP variant 7 (V7) conjugated to near infrared fluorescent dye, Alexa750, targets pancreatic 
ductal adenocarcinoma (PDAC) in human S2VP10 and S2013 pancreatic cancer xenograft mouse 
models with minimal off-target accumulation. At the same time, pH-insensitive K7 pHLIP, where 
a single protonatable Glu residue was replaced by a positively-charged Lys residue, served as a 
control and showed about 100 times less tumor accumulation. Immediately prior to injection of 
the constructs, as well as 4 and 24 hours post injection, mice were imaged by employing of 
multispectral optoacoustic tomography (MSOT). Optoacoustic imaging is an emerging new 
technology with the potential to increase sensitivity and improve spatial resolution. It 
represents a hybrid technique that incorporates advantageous properties of both light and 
sound, since resolution of the optical contrast obeys the rules of ultrasonic diffraction, 
rendering photon scattering irrelevant to image resolution (2, 3). Thus, high-resolution at depth 
of organ or tissue could be achieved in contrast to optical imaging, which is critical for the 
imaging of tumors in humans.  
 
To improve cancer detection it is very important to introduce new imaging modalities, which 
should be accompanied with the development of novel tumor-specific molecular contrast 
probes. There are number of ways of tumor targeting, one of the most popular is based on 
targeting of overexpressed protein biomarkers. However, the genetic instability and 
consequent heterogeneity of cancer cells limit approaches for treatment of tumors by targeting 
specific biomarkers, since clonal selection leads cell populations to overcome the therapy by 
growth of sub-populations that do not express sensitizing levels of the biomarker in question. 
Cytotoxic therapies, whilst treating the majority of cancer cells, may spare multidrug resistant 
clones leading to tumor relapse and treatment failure (4). Moreover, this transient 
depopulation of sensitive tumor cells by chemotherapeutic agents may provide a growth 
advantage to the surviving cells, leading to outgrowth of resistant clones (5). It is therefore 
important to develop alternative approaches, which are based on targeting of tumor 
microenvironment that is less likely to be subject to resistant selection. One such property is 
the acidity that is associated with tumor growth and development, which could serve as a 
universal marker for targeting. Adaptations to the highly acidic microenvironment are critical 
steps in the transition from an avascular pre-invasive tumor to a malignant invasive carcinoma. 
Although the acidity also varies within and among tumors, the general variation favors therapy, 
since more aggressive and more metastatic tumors tend to be more acidic (6).  
 
The promise of exploiting tumor acidosis as a cancer biomarker has not been fully realized in 
clinical practice, even though the acidity has been a known property since the work of Otto 
Warburg nearly a century ago. The problem has been to find a practical way to target acidity, 
since the bulk extracellular pH in diseased tissue is just 0.5-0.8 pH units lower than the 
extracellular pH in healthy tissue (7). From a biological standpoint the change is significant, and 
alters the functions and survival of cells. At the same time, from a chemical standpoint the 
change is small, so very precise tuning of chemical properties would be needed in a targeting 
agent.  But, an important to outline that the pH is lowest at the surfaces of cells compared to 
the bulk extracellular pH  and increases with distance from cellular membrane, and becoming 
normal in the vicinity of blood vessels . So, the average pH in tissue is less informative than the 
pH at cellular surfaces, which needs to be the main target for the development of pH-sensitive 
agents. 
 
One of the unique approaches introduced for the targeting of tumor acidity is based on the 
biophysical principles of pH-dependent interaction of a polypeptide with lipid bilayer of a 
membrane. pH Low Insertion Peptides capable to undergo a pH-induced membrane-associated 
folding (8), which results in targeting of cancer cells in acidic tumors with minimal accumulation 
in healthy tissue with normal extracellular pH (Figure 1). pHLIP peptides possess dual delivery 
capabilities, making use of the energy of folding to translocate polar cargo molecules across 
phospholipid bilayer of membrane and/or tether molecules to the cell surface. Also, the 
process of peptide folding within a membrane ensures a high cooperativity of the transition, 
which cannot be achieved by simple diffusion. Since pHLIPs are in equilibrium between 
membrane bound and non-bound configurations at normal pH, they are capable of sensing pH 
at the cell surface. As soon as pH drops (even on a half of pH unit), the Asp and Glu residues are 
protonated and affinity of peptides to membrane is enhanced dramatically, which triggers 
folding in membrane and release of energy. Depending on pHLIP sequence, protonatable 
residues could be differently located on membrane surface, which directly affects the rate of 
the protonation events at various pHs, and thus pK of peptides insertion into the membrane. 
Family of pHLIP peptides with pK of insertion varying from 4.5 to 6.5 was introduced (9) and it 
was confirmed that tumor targeting is indeed pH-dependent (10, 11). pHLIPs variant 7 (V7) and 
variant 3 (V3) were selected as lead candidates for pH-specific delivery of imaging and 
therapeutic agents to tumors of different origins. It was shown that the fluorescent pHLIPs can 
localize and specifically detect pancreatic ductal adenocarcinoma in human xenografts as well 
as PDAC and PanIN lesions in genetically engineered mouse models (12).  
 
 
Kimbrough and colleagues also employed pHLIP variant 7 for the targeting of PDAC and 
demonstrated that precise mapping of tumors could be achieved by optoacoustic imaging. 
Pancreatic ductal adenocarcinoma remains highly lethal because of its advanced stage at 
presentation. The lack of specific symptoms (due to the physical position of the organ), and the 
lack of sensitive and specific biomarkers, make obtaining a diagnosis difficult at an early stage. 
For these reasons, there is an urgent need for tools to aid in the early and specific detection of 
PDAC prior to the development of micro-metastatic disease. The molecular imaging with 
targeted probes could potentially improve the early diagnosis, staging, and monitoring of PDAC. 
Endoscopic, laparoscopic, or handheld applications of MSOT in combination with pH-sensitive 
pHLIP probes could aid in the detection and staging of pancreatic tumors, help determine 
resectability, assist in identification of viable tumor during surgical intervention, as well as help 
monitor responses to treatment.  
 
Translation of pHLIP technology and MSOT imaging to clinics may lead to improvements in 
imaging, treatment, and monitoring outcome of therapy for tumors of various origins, 
especially highly aggressive and metastatic ones. 
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Figure Legend 
Schematic presentation of pHLIP peptide (red) conjugated with fluorescent dye (yellow) 
interaction with plasma membrane of a normal cell in healthy tissue (A) and a cancer cell in 
tumor (B). The extracellular pH in healthy tissue is around pH7.4. On the other hand, pH 
gradient exists near the surface of cancer cells: the pH near the plasma membrane is lowest 
(around pH6.0-6.2) increasing with distance from the membrane. pHLIP peptides are weakly 
bound to the surface of cell membrane in healthy tissue. However, at low extracellular pH in 
tumors, pHLIPs insert into plasma membrane, tethering imaging probe to cancer cells. In 
tumors, the equilibrium is shifted toward membrane inserted form of the peptide, leading to 
accumulation of the peptide and imaging agent within a tumor. At the same time, in healthy 
tissue, the equilibrium is shifted toward membrane non-bound form of the peptide, which 
results in washing of the peptide from healthy tissue. 
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